Your browser doesn't support javascript.
loading
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Cho, Hanna; Mundada, Nidhi S; Apostolova, Liana G; Carrillo, Maria C; Shankar, Ranjani; Amuiri, Alinda N; Zeltzer, Ehud; Windon, Charles C; Soleimani-Meigooni, David N; Tanner, Jeremy A; Heath, Courtney Lawhn; Lesman-Segev, Orit H; Aisen, Paul; Eloyan, Ani; Lee, Hye Sun; Hammers, Dustin B; Kirby, Kala; Dage, Jeffrey L; Fagan, Anne; Foroud, Tatiana; Grinberg, Lea T; Jack, Clifford R; Kramer, Joel; Kukull, Walter A; Murray, Melissa E; Nudelman, Kelly; Toga, Arthur; Vemuri, Prashanthi; Atri, Alireza; Day, Gregory S; Duara, Ranjan; Graff-Radford, Neill R; Honig, Lawrence S; Jones, David T; Masdeu, Joseph; Mendez, Mario; Musiek, Erik; Onyike, Chiadi U; Riddle, Meghan; Rogalski, Emily J; Salloway, Stephen; Sha, Sharon; Turner, Raymond Scott; Wingo, Thomas S; Wolk, David A; Koeppe, Robert; Iaccarino, Leonardo; Dickerson, Bradford C; La Joie, Renaud; Rabinovici, Gil D.
Afiliação
  • Cho H; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Mundada NS; Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Apostolova LG; Global Brain Health Institute, University of California, San Francisco, California, USA.
  • Carrillo MC; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Shankar R; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Amuiri AN; Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine Indianapolis, Indianapolis, Indiana, USA.
  • Zeltzer E; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Windon CC; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Soleimani-Meigooni DN; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Tanner JA; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Heath CL; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Lesman-Segev OH; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Aisen P; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Eloyan A; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Lee HS; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
  • Hammers DB; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Kirby K; Department of Diagnostic Imaging, Sheba Medical Center, Tel HaShomer, Israel.
  • Dage JL; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Fagan A; Department of Biostatistics, Center for Statistical Sciences, Brown University, Rhode Island, USA.
  • Foroud T; Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Grinberg LT; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Jack CR; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kramer J; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kukull WA; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Murray ME; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Nudelman K; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Toga A; Department of Pathology, University of California - San Francisco, San Francisco, California, USA.
  • Vemuri P; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Atri A; Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
  • Day GS; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Duara R; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Graff-Radford NR; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Honig LS; Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
  • Jones DT; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Masdeu J; Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Mendez M; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Musiek E; Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
  • Onyike CU; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Riddle M; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Rogalski EJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Salloway S; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Sha S; Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
  • Turner RS; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Wingo TS; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Wolk DA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Koeppe R; Department of Neurology, Alpert Medical School, Brown University, Rhode Island, USA.
  • Iaccarino L; Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Dickerson BC; Department of Neurology, Alpert Medical School, Brown University, Rhode Island, USA.
  • La Joie R; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Rabinovici GD; Department of Neurology, Georgetown University, Washington, USA.
Alzheimers Dement ; 19 Suppl 9: S98-S114, 2023 11.
Article em En | MEDLINE | ID: mdl-37690109
ABSTRACT

INTRODUCTION:

We aimed to describe baseline amyloid-beta (Aß) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD).

METHODS:

We analyzed baseline [18F]Florbetaben (Aß) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aß+) from EOnonAD (Aß-) based on the combination of visual read by expert reader and image quantification.

RESULTS:

243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants.

DISCUSSION:

LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. HIGHLIGHTS 72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos